Emerging Bispecifics Myeloma Patients Should Know About | Dr. Joshua Richter | The Patient Story

(21:2)

Dr. Joshua Richter Discusses Multiple Myeloma Clinical Trials

(2:1econd)

Response Rate on Phase 1/2 Trial REGN5458 (BCMAxCD3 Bispecific Antibody) for RRMM Patients

(7:18)

What Are Bispecifics in Multiple Myeloma? (For Patients and Caregivers) | Dr. Joshua Richter

(5:20)

FAQs on Biomarkers in Multiple Myeloma

(58:40)

Old School 'Death' Style Mix

(10:51)

Multiple Myeloma in 2023: What Patients \u0026 Caregivers Need to Know Now! | The Patient Story

(31:15)

Thriving with Myeloma: What You Should Know About Care and Treatment

(31:4)

Using Daratumumab to Treat High-Risk Myeloma Patients

(1:47)

Justin Hamner and Rob Newell on MERCER-194

(3:13:55)

Updates on Teclistamab, Talquetamab, and CARVYKTI | Mark Wildgust, PHD | ASH 2022

(5:29)

Can You Do This in Livewire?

(12:53)

Questions to Ask My Doctor about New Myeloma Treatments | Dr. Joshua Richter | The Patient Story

(5:2)

Real-world outcomes of autoSCT for multiple myeloma in the first-line setting

(2:)

How to optimize access to CAR-T cell therapies in multiple myeloma

(1:38)

Prevention \u0026 monitoring of infections in patients with multiple myeloma treated with immunotherapies

(1:14)

iSTOPMM study and early MGUS and SMM screening | Joshua Richter, MD | ASH 2021

(1:53)

Bispecific Antibodies | Joshua Richter, MD | ASH 2022

(3:11)

Managing patients with difficult to treat multiple myeloma

(1:49)

Outcomes of patients with myeloma receiving fixed-duration cevostamab

(1:2)

Regeneron bispecific antibody targeting BCMA update | Joshua Richter, MD | ASH 2021

(1:28)

T Cell Re-direction Therapy | Joshua Richter, MD | EHA 2022

(2:18)

Bridging patients with myeloma to subsequent treatments with chemotherapy \u0026 stem cell support

(1:38)

Oncologists Share Why They Pursued Medicine | The Doctor Story (Multiple Myeloma)

(3:56)

What are CELMoDs in Multiple Myeloma (\u0026 When Will They Be Available?) | Dr. Joshua Richter

(3:4)

Safety and efficacy of linvoseltamab in patients with relapsed/refractory (R/R) multiple myeloma

(2:12)

Sequencing BCMA Myeloma Therapies

(58:19)